Spark Therapeutics (NASDAQ:ONCE) has been given a $71.00 price objective by analysts at Sanford C. Bernstein in a research note issued on Wednesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Sanford C. Bernstein’s price objective would indicate a potential upside of 57.04% from the stock’s current price.
A number of other equities analysts have also recently issued reports on ONCE. UBS cut Spark Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $92.00 to $51.00 in a report on Tuesday. BMO Capital Markets set a $73.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a report on Tuesday. SunTrust Banks set a $101.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a report on Monday, October 16th. Chardan Capital decreased their target price on Spark Therapeutics from $100.00 to $60.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Leerink Swann cut Spark Therapeutics from an “outperform” rating to a “market perform” rating and set a $49.00 target price on the stock. in a report on Tuesday. Two analysts have rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the company’s stock. Spark Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $76.19.
Shares of Spark Therapeutics (NASDAQ:ONCE) opened at $45.21 on Wednesday. Spark Therapeutics has a 12 month low of $41.06 and a 12 month high of $91.75.
In other news, Director Hospital Of Philade Children’s sold 1,000,000 shares of Spark Therapeutics stock in a transaction on Thursday, September 21st. The stock was sold at an average price of $84.63, for a total transaction of $84,630,000.00. Following the transaction, the director now owns 3,928,707 shares in the company, valued at $332,486,473.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Daniel Faga sold 1,500 shares of Spark Therapeutics stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total value of $127,500.00. Following the transaction, the insider now owns 1,500 shares in the company, valued at approximately $127,500. The disclosure for this sale can be found here. Insiders have sold 1,068,809 shares of company stock worth $89,809,385 in the last quarter. 7.30% of the stock is currently owned by corporate insiders.
Hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. grew its holdings in shares of Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 389 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Spark Therapeutics in the second quarter valued at about $143,000. Teacher Retirement System of Texas purchased a new position in Spark Therapeutics in the third quarter valued at about $225,000. Prudential Financial Inc. purchased a new position in Spark Therapeutics in the third quarter valued at about $239,000. Finally, Commonwealth Equity Services Inc purchased a new position in Spark Therapeutics in the third quarter valued at about $257,000. Institutional investors and hedge funds own 94.94% of the company’s stock.
WARNING: This news story was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://sportsperspectives.com/2017/12/15/spark-therapeutics-once-pt-set-at-71-00-by-sanford-c-bernstein.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.